| Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells M Arpinati, CL Green, S Heimfeld, JE Heuser, C Anasetti Blood, The Journal of the American Society of Hematology 95 (8), 2484-2490, 2000 | 749 | 2000 |
| Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors E Patin, M Hasan, J Bergstedt, V Rouilly, V Libri, A Urrutia, C Alanio, ... Nature immunology 19 (3), 302-314, 2018 | 253 | 2018 |
| Flow cytometry method validation protocols N Selliah, S Eck, C Green, T Oldaker, J Stewart, A Vitaliti, V Litwin Current Protocols in Cytometry 87 (1), e53, 2019 | 80 | 2019 |
| GMP production and testing of Xcellerated T Cells™ for the treatment of patients with CLL LS Hami, C Green, N Leshinsky, E Markham, K Miller, S Craig Cytotherapy 6 (6), 554-562, 2004 | 78 | 2004 |
| 2019 white paper on recent issues in bioanalysis: FDA immunogenicity guidance, gene therapy, critical reagents, biomarkers and flow cytometry validation (part 3–recommendations … S Piccoli, D Mehta, A Vitaliti, J Allinson, S Amur, S Eck, C Green, ... Bioanalysis 11 (24), 2207-2244, 2019 | 77 | 2019 |
| Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus BA Sullivan, W Tsuji, A Kivitz, J Peng, GE Arnold, MJ Boedigheimer, ... Lupus science & medicine 3 (1), e000146, 2016 | 75 | 2016 |
| Quantitative comparison of conventional and t-SNE-guided gating analyses S Toghi Eshghi, A Au-Yeung, C Takahashi, CR Bolen, MN Nyachienga, ... Frontiers in immunology 10, 1194, 2019 | 57 | 2019 |
| Recommendations for the validation of flow cytometric testing during drug development: I instrumentation CL Green, L Brown, JJ Stewart, Y Xu, V Litwin, TW Mc Closkey Journal of immunological methods 363 (2), 104-119, 2011 | 53 | 2011 |
| Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant RR Redfield, SC Jordan, S Busque, F Vincenti, ES Woodle, N Desai, ... American journal of transplantation 19 (11), 3035-3045, 2019 | 50 | 2019 |
| 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3–LBA/cell-based assays: immunogenicity … L Stevenson, S Richards, R Pillutla, A Torri, J Kamerud, D Mehta, S Keller, ... Bioanalysis 10 (24), 1973-2001, 2018 | 47 | 2018 |
| Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial NG Daver, M Dail, JS Garcia, BA Jonas, KWL Yee, KR Kelly, N Vey, ... Blood 141 (11), 1265-1276, 2023 | 42 | 2023 |
| Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML) CL Green, M Loken, D Buck, HJ Deeg Leukemia 14 (4), 770-772, 2000 | 40 | 2000 |
| Updated results from the venetoclax (Ven) in combination with idasanutlin (Idasa) arm of a phase 1b trial in elderly patients (pts) with relapsed or refractory (R/R) AML … NG Daver, JS Garcia, BA Jonas, KR Kelly, S Assouline, JM Brandwein, ... Blood 134, 229, 2019 | 35 | 2019 |
| Recommendations for the evaluation of specimen stability for flow cytometric testing during drug development L Brown, CL Green, N Jones, JJ Stewart, S Fraser, K Howell, Y Xu, ... Journal of Immunological Methods 418, 1-8, 2015 | 32 | 2015 |
| PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis AT Gerds, BL Scott, PL Greenberg, SK Khaled, TL Lin, DA Pollyea, ... Blood 132, 466, 2018 | 31 | 2018 |
| Role of receptor occupancy assays by flow cytometry in drug development JJ Stewart, CL Green, N Jones, M Liang, Y Xu, DEC Wilkins, M Moulard, ... Cytometry Part B: Clinical Cytometry 90 (2), 110-116, 2016 | 31 | 2016 |
| High‐sensitivity flow cytometric assays: considerations for design control and analytical validation for identification of rare events U Sommer, S Eck, L Marszalek, JJ Stewart, J Bradford, TW McCloskey, ... Cytometry Part B: Clinical Cytometry 100 (1), 42-51, 2021 | 30 | 2021 |
| Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or … NG Daver, DA Pollyea, JS Garcia, BA Jonas, KWL Yee, P Fenaux, ... Blood 132, 767, 2018 | 27 | 2018 |
| Recommendations for the development and validation of flow cytometry‐based receptor occupancy assays CL Green, JJ Stewart, CM Högerkorp, A Lackey, N Jones, M Liang, Y Xu, ... Cytometry Part B: Clinical Cytometry 90 (2), 141-149, 2016 | 24 | 2016 |
| Cyt‐Geist: Current and future challenges in cytometry: Reports of the CYTO 2018 conference workshops K Czechowska, J Lannigan, L Wang, J Arcidiacono, TM Ashhurst, ... Cytometry Part A 95 (6), 598-644, 2019 | 21 | 2019 |
